• 1:中国心衰中心联盟
• 2:苏州工业园区心血管健康研究院
• 3:中国心血管健康联盟

摘要(Abstract)：

<正>心力衰竭（简称心衰）是各种原因导致心脏结构和（或）功能异常，使心室收缩和（或）舒张功能发生障碍，是所有心血管疾病发展到中晚期的一组复杂临床综合征~([1])。随着社会经济的发展，人口老龄化及城镇化进程的加速，我国心血管病危险因素对居民健康的影响越加显著~([2])。根据《中国心血管健康与疾病报告2020概要》~([3])，我国的心血管病发病率持续增高，推算心血管病现患人数3.3亿，其中心衰890万。

关键词(KeyWords)： 心力衰竭;中国心衰中心;健康中国;心血管疾病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author):

参考文献(References)：

• [1]中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018,46(10):760-789.
• [2] Bragazzi NL, Zhong W, Shu J,et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990to 2017[J]. Eur J Prev Cardiol,2021,28(15):1682-1690.
• [3]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2020概要[J].中国循环杂志，2021, 36(6):521-545.
• [4] Wang H, Chai K, Du M,et al. Prevalence and incidence of heart failure among urban patients in China:a national population-based analysis[J]. Circ Heart Fail,2021,14(10):e008406.
• [5] Mamas MA, Sperrin M, Watson MC,et al. Do patients have worse outcomes in heart failure than in cancer? A primary carebased cohort study with 10-year follow-up in Scotland[J]. Eur J Heart Fail,2017,19(9):1095-1104.
• [6] Drozd M, Relton SD, Walker AMN,et al. Association of heart failure and its comorbidities with loss of life expectancy[J].Heart,2021,107(17):1417-1421.
• [7] Di Palo KE, Barone NJ. Hypertension and heart failure:prevention, targets, and treatment[J]. Heart Fail Clin,2020,16(1):99-106.
• [8] Pfeffer MA. Heart failure and hypertension:importance of prevention[J]. Med Clin North Am,2017,101(1):19-28.
• [9] Hao G, Wang X, Chen Z,et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail,2020,22(4):759.
• [10] Triposkiadis F, Karayannis G, Giamouzis G,et al.The sympathetic nervous system in heart failure physiology,pathophysiology, and clinical implications[J]. J Am Coll Cardiol,2009,54(19):1747-1762.
• [11] Shin SY, Lip GYH. Are alpha-adrenergic receptor antagonists beneficial to prevent heart failure? Alpha-adrenergic receptor antagonists revisited[J]. JACC Heart Fail,2018,6(11):926-927.
• [12] Jackevicius CA, Ghaznavi Z, Lu L, et al. Safety of alphaadrenergic receptor antagonists in heart failure[J]. JACC Heart Fail,2018,6(11):917-925.
• [13] Lehrke M, Marx N. Diabetes mellitus and heart failure[J].Am J Cardiol,2017,120(1S):S37-S47.
• [14] Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure:a scientific statement from the American Heart Association and the Heart Failure Society of America:this statement does not represent an update of the2017 ACC/AHA/HFSA heart failure guideline update[J].Circulation,2019,140(7):e294-e324.
• [15] Natali A, Nesti L, TricòD, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function:a narrative review of clinical evidence[J].Cardiovasc Diabetol,2021,20(1):196.
• [16] Petrie MC, Verma S, Docherty KF, et al. Effect of dapaglifl ozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes[J].JAMA,2020,323(14):1353-1368.
• [17] Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review[J].Diabetologia,2018,61(10):2108-2117.
• [18] Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction:a review[J]. JAMA,2020,324(5):488-504.
• [19] Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2(SGLT-2)inhibitors and glucagon-like peptide-1(GLP-1)receptor agonists for type 2 diabetes:systematic review and network meta-analysis of randomised controlled trials[J]. BMJ,2021,372:m4573.
• [20] Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to:management of hyperglycemia in type 2 Diabetes, 2018.A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J]. Diabetes Care,2020,43(2):487-493.
• [21] Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction:epidemiology, mechanisms and management[J]. Nat Rev Nephrol,2016,12(10):610-623.
• [22] House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease:conclusions from a kidney disease:improving global outcomes(KDIGO)controversies conference[J]. Kidney Int,2019,95(6):1304-1317.
• [23] Yang L, Ye N, Bian W, et al. Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction:a systematic review and metaanalysis[J]. Int Urol Nephrol,2022,54(6):1435-1444.
• [24] Hein AM, Scialla JJ, Edmonston D, et al. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease[J]. JACC Heart Fail,2019,7(5):371-382.
• [25] Capelli I, Gasperoni L, Ruggeri M, et al. New mineralocorticoid receptor antagonists:update on their use in chronic kidney disease and heart failure[J]. J Nephrol,2020,33(1):37-48.
• [26] Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes:a large multinational cohort study[J]. Diabetes Obes Metab,2020,22(9):1607-1618.
• [27] Carlisle MA, Fudim M, DeVore AD, et al. Heart failure and atrial fi brillation, like fi re and fury[J]. JACC Heart Fail,2019,7(6):447-456.
• [28] Prabhu S, Voskoboinik A, Kaye DM, et al. Atrial fi brillation and heart failure-cause or ef fect[J]? Heart Lung Circ,2017,26(9):967-974.
• [29] Zhao L, Wang WYS, Yang X. Anticoagulation in atrial fi brillation with heart failure[J]. Heart Fail Rev,2018,23(4):563-571.
• [30] Obeidat M, Burgess M, Lip GYH. Atrial fi brillation in heart failure:focus on antithrombotic management[J]. Heart Fail Clin,2020,16(1):107-120.
• [31] Güder G, St?rk S. COPD and heart failure:dif ferential diagnosis and comorbidity[J]. Herz,2019,44(6):502-508.
• [32] Horodinschi RN, Bratu OG, Dediu GN, et al. Heart failure and chronic obstructive pulmonary disease:a review[J].Acta Cardiol,2020,75(2):97-104.
• [33] Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use:a Danish nationwide cohort study[J]. Eur J Heart Fail,2018,20(3):548-556.
• [34] Baker JG, Wilcox RG. β-blockers, heart disease and COPD:current controversies and uncertainties[J]. Thorax,2017,72(3):271-276.
• [35] Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment:answers to 10 pivotal issues about heart failure with reduced ejection fraction:a report of the american college of cardiology solution set oversight committee[J]. J Am Coll Cardiol,2021,77(6):772-810.
• [36] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
• [37]郑旭辉，李新立.慢性收缩功能降低性心力衰竭药物治疗的合理性与规范化[J/OL].中华心血管病杂志（网络版），2021, 4:e1000083.(2021-09-06)[2022-04-13]. http：//www.cvjc.org.cn/index.php/Column/columncon/article_id/251.
• [38] Samarendra P. GDMT for heart failure and the clinician’s conundrum[J]. Clin Cardiol,2019,42(12):1155-1161.
• [39] Srivastava PK, DeVore AD, Hellkamp AS, et al. Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients[J].JACC Heart Fail,2021,9(1):28-38.
• [40] Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation,continuation, switching, and withdrawal of heart failure medical therapies during hospitalization[J]. JACC Heart Fail,2019,7(1):1-12.
• [41]国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J].中国循环杂志，2021,36(3):221-238.
• [42] Crespo-Leiro MG,Anker SD,Maggioni AP,et al. European Society of Cardiology Heart Failure Long-Term Registry(ESCHF-LT):1-year follow-up outcomes and differences across regions[J]. Eur J Heart Fail,2016,18(6):613-625.
• [43] Kassem H, Chatila K. Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease:why,when, and how[J]? Curr Opin Nephrol Hypertens,2020,29(2):258-263.
• [44] Hasin T, Davarashvili I, Michowitz Y, et al. Association of guideline-based medical therapy with malignant arrhythmias and mortality among heart failure patients implanted with cardioverter defi brillator(ICD)or cardiac resynchronizationdefibrillator device(CRTD)[J]. J Clin Med,2021,10(8):1753.
• [45] Mullens W, Auricchio A, Martens P, et al. Optimized implementation of cardiac resynchronization therapy:a call for action for referral and optimization of care:a joint position statement from the Heart Failure Association(HFA),European Heart Rhythm Association(EHRA), and European Association of Cardiovascular Imaging(EACVI)of the European Society of Cardiology[J]. Eur J Heart Fail,2020,22(12):2349-2369.
• [46] Truby LK, Rogers JG. Advanced hea rt fai lure:epidemiology, diagnosis, and therapeutic approaches[J].JACC Heart Fail,2020,8(7):523-536.
• [47] Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure(China-HF)registry[J]. J Card Fail,2017,23(12):868-875.
• [48] Chang LL, Xu H, DeVore AD, et al. Timing of postdischarge follow-up and medication adherence among patients with heart failure[J]. J Am Heart Assoc,2018,7(7):e007998.